Ananya Gopika Nair1, Vasily Giannakeas2,3, John L Semple1,2,4,5, Steven A Narod1,2,3,6, David W Lim7,8. 1. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 2. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 3. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 4. Department of Surgery, Women's College Hospital, Toronto, ON, Canada. 5. Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. 6. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. 7. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. david.lim@wchospital.ca. 8. Department of Surgery, Women's College Hospital, Toronto, ON, Canada. david.lim@wchospital.ca.
Abstract
BACKGROUND: Breast reconstruction is generally discouraged in women with inflammatory breast cancer (IBC). Nevertheless, reconstruction rates are increasing in this population. OBJECTIVE: We aimed to determine contemporary trends and predictors of breast reconstruction use and its impact on mortality among IBC patients. METHODS: Demographic, clinicopathologic, and follow-up data for women with non-metastatic IBC having mastectomy between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Rates and predictors of immediate breast reconstruction, along with survival outcomes between the breast reconstruction and no reconstruction groups were calculated. To account for selection bias, a propensity score analysis matching one reconstruction patient to three no reconstruction patients was performed. RESULTS: A total of 4076 women with non-metastatic IBC who underwent mastectomy (388 [9.5%] with breast reconstruction and 3688 [90.5%] without) were included. The proportion of women undergoing breast reconstruction and contralateral prophylactic mastectomy increased from 6.2 to 15.3% and 12.9 to 29.6%, respectively, between 2004 and 2015. Younger age, higher annual income, metropolitan residence, and bilateral mastectomy predicted breast reconstruction use. The 10-year breast cancer-specific survival was 62.9% for women having breast reconstruction and 47.6% for women not having breast reconstruction. After propensity-matched analysis, 10-year cancer-specific survival was similar between the reconstruction (56.6%) and no reconstruction (62.2%) groups (adjusted hazard ratio 0.96, 95% confidence interval 0.79-1.16; p = 0.65). CONCLUSIONS: Breast reconstruction rates continue to rise among IBC patients, particularly young women and women with access to reconstruction. Breast reconstruction is not associated with inferior breast cancer-specific survival and can be an option for select patients.
BACKGROUND: Breast reconstruction is generally discouraged in women with inflammatory breast cancer (IBC). Nevertheless, reconstruction rates are increasing in this population. OBJECTIVE: We aimed to determine contemporary trends and predictors of breast reconstruction use and its impact on mortality among IBC patients. METHODS: Demographic, clinicopathologic, and follow-up data for women with non-metastatic IBC having mastectomy between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Rates and predictors of immediate breast reconstruction, along with survival outcomes between the breast reconstruction and no reconstruction groups were calculated. To account for selection bias, a propensity score analysis matching one reconstruction patient to three no reconstruction patients was performed. RESULTS: A total of 4076 women with non-metastatic IBC who underwent mastectomy (388 [9.5%] with breast reconstruction and 3688 [90.5%] without) were included. The proportion of women undergoing breast reconstruction and contralateral prophylactic mastectomy increased from 6.2 to 15.3% and 12.9 to 29.6%, respectively, between 2004 and 2015. Younger age, higher annual income, metropolitan residence, and bilateral mastectomy predicted breast reconstruction use. The 10-year breast cancer-specific survival was 62.9% for women having breast reconstruction and 47.6% for women not having breast reconstruction. After propensity-matched analysis, 10-year cancer-specific survival was similar between the reconstruction (56.6%) and no reconstruction (62.2%) groups (adjusted hazard ratio 0.96, 95% confidence interval 0.79-1.16; p = 0.65). CONCLUSIONS: Breast reconstruction rates continue to rise among IBC patients, particularly young women and women with access to reconstruction. Breast reconstruction is not associated with inferior breast cancer-specific survival and can be an option for select patients.
Authors: Ashley B Simpson; Devina McCray; Craig Wengler; Joseph P Crowe; Risal Djohan; Rahul Tendulkar; Colin O'Rourke; Stephen R Grobmyer; Stephanie A Valente Journal: Ann Surg Oncol Date: 2016-09-08 Impact factor: 5.344
Authors: Melinda M Mortenson; Philip D Schneider; Vijay P Khatri; Thomas R Stevenson; Thomas P Whetzel; Eiler J Sommerhaug; James E Goodnight; Richard J Bold Journal: Arch Surg Date: 2004-09
Authors: Arjun Menta; Tamer M Fouad; Anthony Lucci; Huong Le-Petross; Michael C Stauder; Wendy A Woodward; Naoto T Ueno; Bora Lim Journal: Surg Clin North Am Date: 2018-05-24 Impact factor: 2.741
Authors: Massimo Cristofanilli; Vicente Valero; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Ana Maria Gonzalez-Angulo; Nour Sneige; Rabiul Islam; Naoto T Ueno; Thomas A Buchholz; Sonja E Singletary; Gabriel N Hortobagyi Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Rahul D Tendulkar; Sana Rehman; Monica E Shukla; Chandana A Reddy; Halle Moore; G Thomas Budd; Jill Dietz; Joseph P Crowe; Roger Macklis Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-05 Impact factor: 7.038
Authors: W W Thoms; M D McNeese; G H Fletcher; A U Buzdar; S E Singletary; M J Oswald Journal: Int J Radiat Oncol Biol Phys Date: 1989-10 Impact factor: 7.038